Capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with fulvestrant was approved by the Food and Drug Administration on November 16, 2023, for adult patients with hormone receptor (HR)...
advanced-breast-cancer-treatment
advanced-breast-cancer-treatment